Top

Published in:

01-04-2016 | Research Article

Role of SPECT-CT in breast cancer sentinel node biopsy when internal mammary chain drainage is observed

Authors: J. Serrano-Vicente, J. I. Rayo-Madrid, M. L. Domínguez-Grande, J. R. Infante-Torre, L. García-Bernardo, M. Moreno-Caballero, F. Medina-Romero, C. Durán-Barquero

Published in: Clinical and Translational Oncology | Issue 4/2016

Abstract

Introduction

SPECT-CT in the detection of the sentinel lymph node (SLN) of breast cancer offers known advantages over conventional planar lymphoscintigraphy. Sometimes, it shows atypical findings like mediastinal lymphatic drainage. We have evaluated these atypical findings showed by SPECT-CT performed in patients with migration to the internal mammary chain (IMC) and their roles in the management of the patients.

Materials and methods

We reviewed the 56 lymphoscintigraphies (planar and SPECT-CT) of 56 women (average age: 55 years) diagnosed with breast cancer with IMC migration observed in the planar images. We compared the two techniques, obtaining the number of depicted nodes, atypical locations, their exact anatomical location and their role in the management of the patient.

Results

Planar images showed a total number of 81 IMC nodes. SPECT-CT showed 74 nodes in the IMC territory and 14 mediastinal lymphatic nodes in 6 patients. Out of the 81 IMC nodes reported by planar images, seven corresponded to mediastinal nodes. Planar and hybrid images showed 110 and 130 axillary nodes, respectively. SPECT-CT showed additional findings in five patients: three infraclavicular and two supraclavicular nodes that were exactly located. One intramammary node was discarded by the SPECT-CT as a focal skin contamination.

Conclusion

Mediastinal nodes are unexpected, but not uncommon findings that are important in the planning of SLN biopsy. SPECT-CT found more nodes than planar images, being able to separate mediastinal and IMC nodes, helping to exactly depict the SLN and its relations with anatomical structures.

Krag D, Weaver D, Ashikaga T, Moffat F, Klimberg VS, Shriver C, et al. The sentinel node in breast cancer-a multicenter validation study. N Engl J Med. 1998;339:941–6.CrossRefPubMed

McMasters KM, Tuttle TM, Carlson DJ, Brown CM, Noyes RD, Glaser RL, et al. Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine axillary dissection in multiinstitutional practice when optimal technique is used. J Clin Oncol. 2000;18:2560–6.PubMed

Shivers S, Cox C, Leight G, Beauchamp D, Blumencranz P, Ross M, et al. Final results of the Department of Defense multicenter breast lymphatic mapping trial. Ann Surg Oncol. 2002;9:248–55.CrossRefPubMed

D’Angelo-Donovan DD, Dickson-Witmer D, Petrelli NJ. Sentinel lymph node biopsy in breast cancer: a history and current clinical recommendations. Surg Oncol. 2012;21:196–200.CrossRefPubMed

Schwartz GF, Giuliano AE, Veronesi U. Consensus Conference Committee. Proceedings of the consensus conference on the role of sentinel lymph node biopsy in carcinoma of the breast, April 19–22, 2001, Philadelphia, Pennsylvania. Cancer. 2002;94:2542–2551.

Martin RC 2nd, Edwards MJ, Wong SL, Tuttle TM, Carlson DJ, Brown CM, et al. Practical guidelines for optimal gamma probe detection of sentinel lymph nodes in breast cancer: results of a multi-institutional study. For the University of Louisville Breast Cancer Study Group. Surgery. 2000;128:139–44.CrossRefPubMed

Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V, et al. A randomized comparison of sentinel node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003;349:546–53.CrossRefPubMed

Giuliano AE, Haigh PI, Brennan MB, Hansen NM, Kelley MC, Ye W, et al. Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node-negative breast cancer. J Clin Oncol. 2000;18:2553–9.PubMed

Schrenk P, Rieger R, Shamiyeh A, Wayand W. Morbidity following sentinel lymph node biopsy versus axillary lymph node dissection for patients with breast carcinoma. Cancer. 2000;88:608–14.CrossRefPubMed

10.

Lerman H, Metser U, Lievshitz G, Sperber F, Shneebaum S, Even-Sapir E. Lymphoscintigraphic sentinel node identification in patients with breast cancer: the role of SPECT-CT. Eur J Nucl Med Mol Imaging. 2006;33:329–37.CrossRefPubMed

11.

Bybel B, Brunken RC, DiFilippo FP, Neumann DR, Wu G, Cerqueira MD. SPECT/CT imaging: clinical utility of an emerging technology. Radiographics. 2008;28:1097–113.CrossRefPubMed

12.

Vercellino L, Ohnona J, Groheux D, Slama A, Colletti PM, Chondrogiannis S, et al. Role of SPECT/CT in sentinel lymph node detection in patients with breast cancer. Clin Nucl Med. 2014;39:431–6.CrossRefPubMed

13.

Pecking AP, Wartski M, Cluzan RV, Bellet D, Albérini JL. SPECT-CT fusion imaging radionuclide lymphoscintigraphy: potential for limb lymphedema assessment and sentinel node detection in breast cancer. Cancer Treat Res. 2007;135:79–84.CrossRefPubMed

14.

Husarik DB, Steinert HC. Single-photon emission computed tomography/computed tomography for sentinel node mapping in breast cancer. Semin Nucl Med. 2007;37:29–33.CrossRefPubMed

15.

Lerman H, Lievshitz G, Zak O, Metser U, Schneebaum S, Even-Sapir E. Improved sentinel node identification by SPECT/CT in overweight patients with breast cancer. J Nucl Med. 2007;48:201–6.PubMed

16.

Bourre JC, Payan R, Collomb D, Gallazzini-Crepin C, Calizzano A, Desruet MD, et al. Can the sentinel lymph node technique affect decisions to offer internal mammary chain irradiation? Eur J Nucl Med Mol Imaging. 2009;36:758–64.CrossRefPubMed

17.

Estourgie SH, Tanis PJ, Nieweg OE, Valdés Olmos RA, Rutgers EJ, Kroon BB. Should the hunt for internal mammary chain sentinel nodes begin? An evaluation of 150 breast cancer patients. Ann Surg Oncol. 2003;10:935–41.CrossRefPubMed

18.

Paredes P, Vidal-Sicart S, Zanón G, Pahisa J, Fernández PL, Velasco M, et al. Clinical relevance of sentinel lymph nodes in the internal mammary chain in breast cancer patients. Eur J Nucl Med Mol Imaging. 2005;32:1283–7.CrossRefPubMed

19.

Madsen E, Gobardhan P, Bongers V, Albregts M, Burgmans J, De Hooge P, et al. The impact on post-surgical treatment of sentinel lymph node biopsy of internal mammary lymph nodes in patients with breast cancer. Ann Surg Oncol. 2007;14:1486–92.CrossRefPubMedPubMedCentral

20.

Postma EL, van Wieringen S, Hobbelink MG, Verkooijen HM, van den Bongard HJ, Borel Rinkes IH, et al. Sentinel lymph node biopsy of the internal mammary chain in breast cancer. Breast Cancer Res Treat. 2012;134:735–41.CrossRefPubMedPubMedCentral

21.

Groheux D, Ferré R, Rubello D, Vercellino L, Hindié E. Breast cancer patient with an uncommon lymphatic drainage evidenced by SPECT/CT. Clin Nucl Med. 2014;39:176–9.

22.

Kroman N, Wohlfahrt J, Mouridsen HT, Melbye M. Influence of tumor location on breast prognosis. Int J Cancer. 2003;105:524–45.CrossRef

23.

Gallowitsch HJ, Kraschl P, Igerc I, Hussein T, Kresnik E, Mikosch P, et al. Sentinel node SPECT-CT in breast cancer. Can we expect any additional and clinically relevant information? Nuklearmedizin. 2007;46:252–6.PubMed

24.

Coffey JP, Hill JC. Breast sentinel node imaging with low-dose SPECT/CT. Nucl Med Commun. 2010;31:107–11.CrossRefPubMed

25.

Law M, Ma WH, Leung R, Wong KK, Ho WY, Kwong A. Evaluation of patient effective dose from sentinel lymph node lymphoscintigraphy in breast cancer: a phantom study with SPECT/CT and ICRP-103 recommendations. Eur J Radiol. 2012;81:717–20.CrossRef

26.

Zakaria S, Degnim AC, Kleer CG, Diehl KA, Cimmino VM, Chang AE, et al. Sentinel lymph node biopsy for breastcancer: how many nodes are enough? J Surg Oncol. 2007;96:554–9.CrossRefPubMed

27.

Yi M, Meric-Bernstam F, Ross MI, Akins JS, Hwang RF, Lucci A, et al. How many sentinel lymph nodes are enough during sentinel lymph node dissection for breast cancer? Cancer. 2008;113:30–7.CrossRefPubMedPubMedCentral

28.

Ortín-Pérez J, Vidal-Sicart S, Duch J, Doménech B, Pons F. Bilateral drainage in the internal mammary chain in the detection of the sentinel lymph node in a breast tumor. Rev Esp Med Nucl. 2009;28:128–9.CrossRefPubMed

Title: Role of SPECT-CT in breast cancer sentinel node biopsy when internal mammary chain drainage is observed
Authors: J. Serrano-Vicente
J. I. Rayo-Madrid
M. L. Domínguez-Grande
J. R. Infante-Torre
L. García-Bernardo
M. Moreno-Caballero
F. Medina-Romero
C. Durán-Barquero
Publication date: 01-04-2016
Publisher: Springer Milan
Published in: Clinical and Translational Oncology / Issue 4/2016
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-015-1384-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Materials and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2016

Comparison of ILK and ERP29 expressions in benign and malignant pancreatic lesions and their clinicopathological significances in pancreatic ductal adenocarcinomas

Spanish Society of Radiation Oncology clinical guidelines for stereotactic body radiation therapy in lymph node oligometastases

Evidence-based recommendations of postoperative radiotherapy in lung cancer from Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society)

Association between downexpression of MiR-203 and poor prognosis in non-small cell lung cancer patients

Pentoxifylline during steroid window phase at induction to remission increases apoptosis in childhood with acute lymphoblastic leukemia

High pKDR immunohistochemical expression is an unfavourable prognostic biomarker in patients with advanced colorectal cancer treated with chemotherapy plus bevacizumab

Keynote webinar | Spotlight on antibody–drug conjugates in cancer